The Cold Spring Harbor Laboratory (CSHL) Cancer Center is a premier cancer research center that uses innovative and collaborative approaches to address some of the most pressing challenges facing cancer biologists and cancer patients today. In particular, research in CSHL Cancer Center is focused on two primary problems: improving cancer diagnostics and increasing therapeutic effectiveness. Researchers in the CSHL Cancer Center are employing cutting edge genetic and genomic approaches to molecularly characterize cancer. The goals of this research are to both develop new diagnostic tools and to also define cancer subtypes so that clinicians will be able to select the most effective therapeutic approaches. CSHL Cancer Center researchers are at the forefront of developing and applying these genomic approaches; discoveries like single cell sequencing have the power to revolutionize diagnostics and are already demonstrating tremendous potential in the clinic. The CSHL Cancer Center is building upon its outstanding foundation in basic discovery science to identify and develop new therapeutic targets for multiple tumor types. More than ten years ago, the Cancer Center formalized this strategy with the creation of a ?cancer discovery pipeline.? The plan integrated basic cancer biology, human cancer genetics, high-throughput screening technology, and innovative animal models in an effort to improve existing treatments for cancer. This pipeline has been tremendously successful. Cancer Center researchers have discovered new cancer genes, identified potential therapeutic targets, and explored new drug resistance mechanisms. As this basic research continues, the Cancer Center is aiming to extend the pipeline even further into translational research. Over the next five years, as part of a Cancer Therapeutics Initiative, the Cancer Center will bring its basic research discoveries to preclinical and clinical settings. Funding from the National Cancer Institute provides the CSHL Cancer Center with the organizational and financial support needed to make a significant impact on cancer diagnosis and treatment. The three research programs (Gene Regulation & Cell Proliferation; Signal Transduction; Cancer Genetics) provide opportunities for members to come together, maximizing collaboration and communication. The nine Shared Resources provide access to technologies, services, and expertise to enhance productivity and promote multidisciplinary interactions. Essential Developmental Funds enable the Center to remain at the forefront of cancer research. Together, these elements of the CSHL Cancer Center create an environment that supports the level of scientific discovery required to make real progress in improving cancer diagnosis and treatment.

Public Health Relevance

CSHL Cancer Center ? Overall Project Narrative Despite decades of research, more than half a million people die of cancer each year in the US. The goal of the Cold Spring Harbor Laboratory Cancer Center is to have a direct impact on public health by improving both the diagnosis and treatment of cancer. With world-renowned scientists and state-of-the-art facilities, the CSHL Cancer Center is continually making basic research discoveries that provide major new insights into cancer biology. Now, the Cancer Center is poised to translate these findings into clinical applications that will improve the diagnosis and treatment of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Marino, Michael A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cold Spring Harbor Laboratory
Cold Spring Harbor
United States
Zip Code
Fang, Han; Huang, Yi-Fei; Radhakrishnan, Aditya et al. (2018) Scikit-ribo Enables Accurate Estimation and Robust Modeling of Translation Dynamics at Codon Resolution. Cell Syst 6:180-191.e4
Lin, Kuan-Ting; Ma, Wai Kit; Scharner, Juergen et al. (2018) A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma. Genome Res :
Wolff, Robert A; Wang-Gillam, Andrea; Alvarez, Hector et al. (2018) Dynamic changes during the treatment of pancreatic cancer. Oncotarget 9:14764-14790
Ryan, Niamh M; Lihm, Jayon; Kramer, Melissa et al. (2018) DNA sequence-level analyses reveal potential phenotypic modifiers in a large family with psychiatric disorders. Mol Psychiatry 23:2254-2265
Danko, Charles G; Choate, Lauren A; Marks, Brooke A et al. (2018) Dynamic evolution of regulatory element ensembles in primate CD4+ T cells. Nat Ecol Evol 2:537-548
Ahrens, Sandra; Wu, Melody V; Furlan, Alessandro et al. (2018) A Central Extended Amygdala Circuit That Modulates Anxiety. J Neurosci 38:5567-5583
Zhang, Tao; Wu, Yen-Ching; Mullane, Patrick et al. (2018) FUS Regulates Activity of MicroRNA-Mediated Gene Silencing. Mol Cell 69:787-801.e8
Arun, Gayatri; Diermeier, Sarah D; Spector, David L (2018) Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends Mol Med 24:257-277
Giuliano, Christopher J; Lin, Ann; Smith, Joan C et al. (2018) MELK expression correlates with tumor mitotic activity but is not required for cancer growth. Elife 7:
Li, Jiahe; Wu, Connie; Wang, Wade et al. (2018) Structurally modulated codelivery of siRNA and Argonaute 2 for enhanced RNA interference. Proc Natl Acad Sci U S A 115:E2696-E2705

Showing the most recent 10 out of 380 publications